The FDA removed the metal-implant contraindication for the Provant Therapy System, making Provant available for use in patients with metallic joint-replacement components and internal-fixation devices. Provant uses pulsed radio-frequency (RF) waves to treat postoperative pain and edema in superficial soft tissue. The prescription device, which is used by patients at home, includes an RF generator that induces the production of endogenous opioids in keratocytes. Scott Brooks, CEO of Provant’s manufacturer, Regenesis Biomedical, said the company is now reaching out to orthopaedic and rehabilitation clinicians to educate them on the benefits of the therapy.